SCHEMBL1640293

SCHEMBL1640293

O=C(Cc1ccnc(Cl)n1)c1cccc(NC(=O)c2cc(F)ccc2F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 1/20 0.45
KCNQ3 O43525 2/20 0.44
KCNQ2 O43526 2/20 0.44
KCNQ5 Q9NR82 1/20 0.44
LCLAT1 Q6UWP7 2/20 0.43
CSF1R P07333 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TRPV1 Q8NER1 1/20 0.41
KCNE1 P15382 1/20 0.40
KCNQ1 P51787 1/20 0.40
ALDH1A1 P00352 1/20 0.40
PARP1 P09874 1/20 0.40
CES1 P23141 2/20 0.39
BRAF P15056 1/20 0.39
CXCR2 P25025 1/20 0.39
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1640536 0.86 KCNQ3 (0.45) KCNQ3KCNQ2KCNQ5MEN1KMT2A
SCHEMBL3422489 0.81 NPC1 (0.42) MEN1KMT2ASMN1; SMN2TRPV1ALDH1A1
SCHEMBL1640323 0.79 KDR (0.48)
SCHEMBL1642332 0.79 FADS1 (0.43) FADS1KCNQ3KCNQ2KCNQ5LCLAT1
SCHEMBL1640594 0.79 TYK2 (0.43) KCNQ3KCNQ2KCNQ5MEN1KMT2A
SCHEMBL12726478 0.78 KDR (0.47)
SCHEMBL310379 0.77 MEN1 (0.41) KCNQ3KCNQ2KCNQ5MEN1KMT2A
SCHEMBL12726473 0.77 ABL1 (0.46) LCLAT1ALDH1A1BRAFNPC1RAB9A
SCHEMBL1640427 0.77 HDAC1 (0.45) MEN1KMT2ASMN1; SMN2ALDH1A1PARP1
SCHEMBL9988807 0.76 ALDH1A1 (0.45) MEN1KMT2ASMN1; SMN2ALDH1A1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
EP-2231625-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-29 EP disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 WO disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors PDXK, MAP3K1, MAP4K2 FADS1 4718/4885KCNQ3 2443/4885KCNQ2 2448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.